Antabio SAS
This article was originally published in Start Up
Executive Summary
Antabio SAS is taking an antivirulence rather than an antibiotic approach to treat gram-negative nosocomial infections. When combined with marketed antibiotics, the compounds in its pipeline have potential to target key virulence pathways in pathogenic bacteria, and thus reduce patient mortality and associated costs.
You may also be interested in...
Financings Of The Fortnight Ponders The Meaning Of The Best Year For Biotech IPOs Since 2007
Plus news on recent financings by Regulus, Aragon, Antabio and Asceneuron.
Start-Up Previews (07/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Alzheimer's Start-Ups Face A Discovery And Clinical Crossroads," features profiles of AlzProtect, Axerion Therapeutics, Cognition Therapeutics and Galantos Pharma. "The Future of Laparoscopy: Single Incision, NOTES And Robots," features profiles of EndoControl, Ovesco Endoscopy, SurgiQuest and Virtual Incision. Plus these Start-Ups Across Health Care: Antabio, Beta-Stim, CMP Therapeutics, Elixir Medical, Kerecis, Optivia Biotechnology, Quanterix and reinnervate.
Start-Up Previews (07/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Alzheimer's Start-Ups Face A Discovery And Clinical Crossroads," features profiles of AlzProtect, Axerion Therapeutics, Cognition Therapeutics and Galantos Pharma. "The Future of Laparoscopy: Single Incision, NOTES And Robots," features profiles of EndoControl, Ovesco Endoscopy, SurgiQuest and Virtual Incision. Plus these Start-Ups Across Health Care: Antabio, Beta-Stim, CMP Therapeutics, Elixir Medical, Kerecis, Optivia Biotechnology, Quanterix and reinnervate.